Ensem Therapeutics, a Boston, MA-based biotechnology firm, raised $67M in Sequence A funding.
The spherical was led by GGV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui & Co. World Funding, and CBC Group.
The corporate intends to make use of the funds to additional advance its Kinetic Ensemble platform and speed up R&D pipeline.
Led by Sean Cao, CEO, Ensembles Therapeutics is a drug discovery and improvement firm that leverages its Kinetic Ensemble platform to develop modern small molecule precision medicines for oncology, with potential growth into genetic problems and different illness areas. ENSEM integrates computational and AI deep studying methodologies with superior experimental strategies to establish non-obvious binding pockets and speed up structure-based drug design, with a concentrate on high-value and difficult-to-drug targets.